QbD: A novel approach for formulation and optimization of colon targeted drug delivery system containing mebeverine HCl
Department of Pharmaceutics, V.L. College of Pharmacy, Raichur, Karnataka, India.
Research Article
Magna Scientia Advanced Research and Reviews, 2023, 09(01), 071–081
Article DOI: 10.30574/msarr.2023.9.1.0123
Publication history:
Received on 17 July 2023; revised on 06 September 2023; accepted on 09 September 2023
Abstract:
The aim of the work is to study the programmed release of model antispasmodic drug Mebeverine HCl based on pulsatile principle to target colon proximity. Compression coated tablets included core tablet consisting of Croscarmellose as super disintegrant and pulsatile layer comprising impermeable Ethocel cup and mixture of Keltone, Eudragit S100, Ethocel as swellable and rupturable layer. The prepared core tablet was evaluated for weight variation, hardness, thickness, friability, drug content, disintegration time and in vitro dissolution studies. For optimization Box-Behnken design was employed to study the effect of independent variables viz., weight ratio of Keltone (X1), Eudragit S100 (X2), Ethocel (X3) on dependent variables viz., t10 (Y1), t50 (Y2) and Q12 (Y3). Results revealed positive influence of independent factors on responses. The data were statistically analyzed using ANOVA and were found to be statistically significant (P < 0.05). Mathematical modeling for kinetic studies revealed that the release profile after lag time followed first order kinetics. The results concluding that a successful pulsatile drug delivery system of Mebeverine HCl was developed.
Keywords:
Mebeverine HCl; Eudragit S100; Croscarmellose; Box Behnken Design; Optimization
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0